Year: 2026
Type: article
Abstract: Mutations in TP53 occur across many cancers, yet the intracellular location of the p53 protein makes it difficult to target with traditional antibody-based therapies. However, mutant peptides, including those derived from p53, can be displayed by human leukocyte antigen (HLA) molecules on the cancer cell surface as peptide-HLA (pHLA) complexes, offering a route to selectively target intracellular mutant proteins. While potentially attractive, these pHLA complexes are often scarce on tumor cells and differ from their normal counterparts by only one amino acid, making selective recognition technically challenging.
Source: Molecular Therapy Oncology
Author: Jacqueline Douglass
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $3,900
OpenAlex ID: W7236198854
